Former MedImmune execs raise $10 million for new start-up Zyngenia
This article was originally published in Scrip
Executive Summary
A number of former MedImmune executives have launched a new biotechnology company called Zyngenia with $10 million in series A funding from New Enterprise Associates (NEA).